A Phase II Study With a Safety Run-in Phase Evaluating Vosaroxin With Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia and Intermediate/Adverse Genetic Risk or Myelodysplastic Syndrome With Excess Blasts-2 (MDS-EB-2) - AMLSG 24-15

The main part of this trial is a phase II study of vosaroxin with azacitidine in older patients with newly diagnosed AML and intermediate or adverse genetic risk or MDS-EB-2. An initial safety run-in phase of the study will be performed administering the study drug vosaroxin with azacitidine in up to 18 patients. After completion of the run-in phase, toxicity and response data will be provided to the external Data and Safety Monitoring Board (DSMB) and the Trial Committee by the Coordinating Investigator. The Trial Committee will decide on the basis of these data and the recommendation of the DSMB on dose modification and the vosaroxin dose for the phase II part of the study, which will include 150 patients in total.

开始日期2018-04-19

申办/合作机构

Universität Ulm

[+1]

NCT02658487

/ Active, not recruiting临床2期IIT

Phase II Trial of Vosaroxin in Combination With Infusional Cytarabine in Patients With Untreated AML

This phase II trial studies how well vosaroxin and cytarabine work in treating patients with untreated acute myeloid leukemia. Drugs used in chemotherapy, such as vosaroxin and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

开始日期2016-03-01

申办/合作机构

The Vanderbilt-Ingram Cancer Center

[+1]

NCT02485353

/ TerminatedN/AIIT

Pilot Study of Vosaroxin and Cytarabine for the Treatment of Adults 60 Years of Age or Older With Previously Untreated AML

This is a pilot efficacy assessment clinical trial of vosaroxin and cytarabine for the treatment of adults 60 years of age or older with previously untreated acute myeloid leukemia. A total of 17 evaluable patients are planned to be treated on the study.

开始日期2015-10-20

申办/合作机构

The Indiana University School of Medicine

100 项与伏利拉辛相关的临床结果

登录后查看更多信息

100 项与伏利拉辛相关的转化医学

登录后查看更多信息

100 项与伏利拉辛相关的专利（医药）

登录后查看更多信息

项与伏利拉辛相关的文献（医药）

2024-12-01·Chemical Biology & Drug Design

Discovery of Voreloxin as a Dual‐Selective Stabilizer for c‐Myc/Bcl‐2 G‐Quadruplexes in Leukemia

Article

作者: Gao, Jian ; Wang, Shangzhao ; Yao, Longsheng ; Qu, Xinxin ; Han, Zheng ; Jia, Pingting ; Yin, Jiacheng

ABSTRACTOverexpression of c‐Myc is a key factor in the development of leukemia and other malignancies, highlighting the urgent need for novel drugs to inhibit c‐Myc protein levels. DNA G‐quadruplexes (G4) have emerged as potential regulatory targets for c‐Myc expression. Previous studies identified trovafloxacin, a topoisomerase II inhibitor, as a novel c‐Myc G4 stabilizer. In this study, virtual screening based on structural similarity led to the identification of nine derivatives of trovafloxacin, among which voreloxin exhibited potent cytotoxicity in multiple myeloma cells and showed promising therapeutic efficacy in leukemia cells. FRET assays demonstrated that voreloxin specifically stabilized the G4 structures of c‐Myc and Bcl‐2, with minimal effects on the G4 structures of other oncogenes. Moreover, voreloxin significantly reduced the expression levels of c‐Myc and Bcl‐2 in THP‐1 and MOLM‐13 cells. Molecular docking, molecular dynamics (MD) simulations, and MM/GBSA calculations further confirmed the stable binding of voreloxin to both c‐Myc and Bcl‐2 G4s, primarily driven by π‐π stacking and hydrogen bonding interactions. These findings provide valuable insights for the development of G4‐targeting drugs for cancer therapy.

2024-05-01·Journal of Molecular Structure

Thiazole moiety: A promising scaffold for anticancer drug discovery

作者: Anwar, Manal M. ; Kassem, Asmaa F. ; El-Sofany, Walaa I. ; Althomali, Raed H.

A review.Over the past few decades, significant advancements in the discovery of anticancer medicines have yielded various novel agents, both synthetic and natural in origin.Thiazoles are a special type of heterocyclic compound with five members that comprise nitrogen and sulfur atoms.These compounds are vital core scaffolds in a number of significant pharmaceutical drugs including anticancer.It was discovered that several chemotherapy drugs have some naturally occurring chems. and a thiazole nucleus.Some clin. used anticancer medications have thiazole nucleus as a basic component including Vosaroxin, Dabrafenib, patellamide A, dasatinib, epothilones, ixabepilone, tiazofurin, Kud 773, and bleomycin.Recently, thiazole-containing compounds have been effectively developed as possible inhibitors of several anti-cancer targets, including enzyme-linked receptor(s) found on the cell membrane (i.e., polymerase inhibitors) and the cell cycle (i.e., microtubular inhibitors).Addnl., it has been demonstrated that these substances exhibit low toxicity, strong anticancer activity, and great efficacy.The biol. importance of thiazoles in the creation of anticancer medications is discussed in this article, which also reviews recent research on the subject.The results may help in the development of more potent and precisely tailored anticancer medications.

2024-01-01·Biochemistry Research International

Evaluation of the Antibacterial and Antioxidant Properties of Chemical Constituents of the Roots of Woodfordia uniflora: An Integrated Approach of Experimental and Computational Study

Article

作者: Abdissa, Negera ; Endale, Milkyas ; Eswaramoorthy, Rajalakshmanan ; Rentsch, Daniel ; Hunsen, Mo ; Shenkute, Kebede ; Melaku, Yadessa ; Ensermu, Urgessa ; Abera, Bihon

Woodfordia uniflora is a medicinal plant used for the treatment of malaria, toothache, and stomach problems. The root parts of the plant are also used for healing liver disorders. Silica gel chromatography separation of CH2Cl2/MeOH (1:1) and MeOH extracts of roots of W. uniflora result in the isolation of three compounds, namely, bergenin (1), β‐sitosterol (2), and epigallocatechin 3‐gallate (3), reported herein for the first time from the plant. The structure of the isolated compounds was elucidated using NMR (1D and 2D) techniques. Disk diffusion and DPPH assay were used to evaluate the antibacterial and antioxidant activities, respectively. Molecular docking was done by the AutoDock Vina 4.2 program. The pharmacokinetics and toxicity profile of compounds were predicted by Swiss ADME and Pro Tox II online servers. GC‐MS analysis roots of W. uniflora result in the identification of five compounds, of which palmitic acid (34.9%) was the major constituent. The antibacterial activity result indicated that the oil extract had promising activity against P. aeruginosa, E. coli, S. pyogenes, and S. aureus with IZ of 14.3 ± 0.81, 15.0 ± 0.0, 15.6 ± 0.47, and 17.6 ± 0.47 mm, respectively, at 5 mg/mL, compared to ciprofloxacin (1Z 27–30.0 ± 0.0 mm) at 30 μg/mL. MeOH and CH2Cl2/MeOH (1:1) extract showed inhibition against E. coli (IZ of 13.6 ± 0.47 mm) and P. aeruginosa (IZ of 10.0 ± 0.0 mm), respectively, at 200 mg/mL. Bergenin (1) and β‐sitosterol (2) also displayed maximum inhibition of E. coil (IZ of 11.6 ± 0.47) and S. aureus (11.0 ± 0.0 mm), respectively, at 5 mg/mL. The antioxidant activity results showed that CH2Cl2/MeOH (1:1) and MeOH extracts, bergenin (1), and compound 3 displayed potent scavenging DPPH radical with a percentage of inhibition of 76.8 ± 0.12, 77.8 ± 0.08, 71.4 ± 0.08, and 91.2 ± 0.16, respectively, compared to ascorbic acid (93.2% ± 0.04%) at 100 μg/mL. The molecular docking analysis showed that all compounds (1–3) exhibited minimum binding energy toward PDB ID: 1HD2 (−5.2 to −6.3 kcal/mol), compared to ascorbic acid (−5.6 kcal/mol), and toward PDB ID: 1DNU (−8.0 to −10.7 kcal/mol) receptors, compared to ascorbic acid (−5.7 kcal/mol). Toward the PDB ID: 4FM9 receptor, β‐sitosterol (2) and compound 3 exhibited the best binding free energy of −9.1 and −9.8 kcal·mol, respectively, compared to vosaroxin (−7.8 kcal/mol). The drug‐likeness analysis result indicated that bergenin (1) and β‐sitosterol (2) obeyed four and five criteria of Lipinski’s rule, respectively, and are more likely to be administered orally. The in silico toxicity analysis showed none of the compounds would be cytotoxic, mutagenic, or hepatotoxic. The in vitro antioxidant and antibacterial results supported by in silico analysis demonstrated that the roots of W. uniflora have the potential to be therapeutic agents for bacterial infections and free radical–inducing diseases.

项与伏利拉辛相关的新闻（医药）

2024-04-25

·GlobeNewswire-Health Care

XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)

XOMA is entitled to a mid-single digit royalty on global OJEMDA™ sales First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation EMERYVILLE, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has earned a $9 million milestone related to the U.S. Food and Drug Administration’s (FDA) approval of Day One Biopharmaceuticals’ New Drug Application (NDA) for OJEMDA™ (tovorafenib) for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. “This is an important milestone for XOMA and our royalty portfolio, but more importantly, it is a watershed event for children living with low-grade gliomas with BRAF alterations that have relapsed or progressed,” stated Owen Hughes, Chief Executive Officer of XOMA. In March 2021, XOMA paid $13.5 million upfront to acquire the $54 million in potential milestones and mid-single digit royalties associated with tovorafenib, plus a share of potential event-based economics, in addition to the economics associated with vosaroxin, from Viracta Therapeutics. About XOMA CorporationXOMA is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com. Forward-Looking Statements/Explanatory Notes Certain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding the timing and amount of potential commercial payments to XOMA and other developments related to OJEMDA™ (tovorafenib) and the potential of XOMA’s portfolio of partnered programs and licensed technologies generating substantial milestone and royalty proceeds over time. In some cases, you can identify such forward-looking statements by terminology such as “expect,” “may,” “will”, or “could,” the negative of these terms or similar expressions. These forward-looking statements are not a guarantee of XOMA’s performance, and you should not place undue reliance on such statements. These statements are based on assumptions that may not prove accurate, and actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry, including those related to the fact that our product candidates subject to out-license agreements are still being developed, and our licensees may require substantial funds to continue development which may not be available; we do not know whether there will be, or will continue to be, a viable market for the products in which we have an ownership or royalty interest; if the therapeutic product candidates to which we have a royalty interest do not receive regulatory approval, our third-party licensees will not be able to market them; and the impact to the global economy as a result of the COVID-19 pandemic. Other potential risks to XOMA meeting these expectations are described in more detail in XOMA's most recent filing on Form 10-K and in other filings with the Securities and Exchange Commission. Consider such risks carefully when considering XOMA's prospects. Any forward-looking statement in this press release represents XOMA's beliefs and assumptions only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. XOMA disclaims any obligation to update any forward-looking statement, except as required by applicable law. EXPLANATORY NOTE: Any references to “portfolio” in this press release refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. Any references to “assets” in this press release refer strictly to milestone and/or royalty rights associated with individual drug products in development. As of the date of this press release, all assets in XOMA’s milestone and royalty portfolio, except OJEMDA™ (tovorafenib), VABYSMO® (faricimab-svoa), IXINITY® [coagulation factor IX (recombinant)], DSUVIA® (sufentanil sublingual tablet), are investigational compounds. Efficacy and safety have not been established. There is no guarantee that any of the investigational compounds will become commercially available. XOMA Investor ContactXOMA Media ContactJuliane SnowdenKathy VincentXOMA CorporationKV Consulting & Management+1-646-438-9754+1-310-403-8951juliane.snowden@xoma.comkathy@kathyvincent.com

上市批准加速审批

2023-10-31

·GlobeNewswire-Health Care

XOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One’s Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)

FDA has granted Priority Review and assigned a PDUFA target action date of April 30, 2024EMERYVILLE, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has earned a $5 million milestone related to the U.S. Food and Drug Administration’s (FDA) acceptance of Day One Biopharmaceuticals’ New Drug Application (NDA) for tovorafenib as a monotherapy for relapsed or progressive pediatric low-grade glioma (pLGG). The FDA has granted tovorafenib Priority Review and established a Prescription Drug User Fee Act (PDUFA) date of April 30, 2024. “Tovorafenib has the potential to address a key unmet need in children whose low-grade gliomas with BRAF alterations have relapsed or progressed,” stated Owen Hughes, Executive Chairman of XOMA. “A novel, targeted, orally available option has the opportunity to set a new standard-of-care in this patient population.” In March 2021, XOMA paid $13.5 million upfront plus a share of a future event-based milestone, to acquire the $54 million in potential milestones and mid-single digit royalties associated with tovorafenib, in addition to the economics associated with vosaroxin, from Viracta Therapeutics. About XOMA CorporationXOMA is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio with more than 70 assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com. Forward-Looking Statements/Explanatory NotesCertain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding the timing and amount of potential commercial payments to XOMA and other developments related to tovorafenib and the potential of XOMA’s portfolio of partnered programs and licensed technologies generating substantial milestone and royalty proceeds over time. In some cases, you can identify such forward-looking statements by terminology such as “expect,” “may,” “will”, or “could,” the negative of these terms or similar expressions. These forward-looking statements are not a guarantee of XOMA’s performance, and you should not place undue reliance on such statements. These statements are based on assumptions that may not prove accurate, and actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry, including those related to the fact that our product candidates subject to out-license agreements are still being developed, and our licensees may require substantial funds to continue development which may not be available; we do not know whether there will be, or will continue to be, a viable market for the products in which we have an ownership or royalty interest; if the therapeutic product candidates to which we have a royalty interest do not receive regulatory approval, our third-party licensees will not be able to market them; and the impact to the global economy as a result of the COVID-19 pandemic. Other potential risks to XOMA meeting these expectations are described in more detail in XOMA's most recent filing on Form 10-K and in other filings with the Securities and Exchange Commission. Consider such risks carefully when considering XOMA's prospects. Any forward-looking statement in this press release represents XOMA's beliefs and assumptions only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. XOMA disclaims any obligation to update any forward-looking statement, except as required by applicable law. EXPLANATORY NOTE: Any references to “portfolio” in this press release refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. Any references to “assets” in this press release refer strictly to milestone and/or royalty rights associated with individual drug products in development. As of the date of this press release, all assets in XOMA’s milestone and royalty portfolio, except VABYSMO® and IXINITY®, are investigational compounds. Efficacy and safety have not been established. There is no guarantee that any of the investigational compounds will become commercially available. XOMA Investor ContactXOMA Media ContactJuliane SnowdenKathy VincentXOMA CorporationKV Consulting & Management+1 646-438-9754+1 310-403-8951juliane.snowden@xoma.comkathy@kathyvincent.com

优先审批申请上市

2023-10-31

·BioSpace

XOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One’s Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)FDA has granted Priority Review and assigned a PDUFA target action date of April 30, 2024

EMERYVILLE, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has earned a $5 million milestone related to the U.S. Food and Drug Administration’s (FDA) acceptance of Day One Biopharmaceuticals’ New Drug Application (NDA) for tovorafenib as a monotherapy for relapsed or progressive pediatric low-grade glioma (pLGG). The FDA has granted tovorafenib Priority Review and established a Prescription Drug User Fee Act (PDUFA) date of April 30, 2024. “Tovorafenib has the potential to address a key unmet need in children whose low-grade gliomas with BRAF alterations have relapsed or progressed,” stated Owen Hughes, Executive Chairman of XOMA. “A novel, targeted, orally available option has the opportunity to set a new standard-of-care in this patient population.” In March 2021, XOMA paid $13.5 million upfront plus a share of a future event-based milestone, to acquire the $54 million in potential milestones and mid-single digit royalties associated with tovorafenib, in addition to the economics associated with vosaroxin, from Viracta Therapeutics. About XOMA Corporation XOMA is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio with more than 70 assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit Forward-Looking Statements/Explanatory Notes Certain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding the timing and amount of potential commercial payments to XOMA and other developments related to tovorafenib and the potential of XOMA’s portfolio of partnered programs and licensed technologies generating substantial milestone and royalty proceeds over time. In some cases, you can identify such forward-looking statements by terminology such as “expect,” “may,” “will”, or “could,” the negative of these terms or similar expressions. These forward-looking statements are not a guarantee of XOMA’s performance, and you should not place undue reliance on such statements. These statements are based on assumptions that may not prove accurate, and actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry, including those related to the fact that our product candidates subject to out-license agreements are still being developed, and our licensees may require substantial funds to continue development which may not be available; we do not know whether there will be, or will continue to be, a viable market for the products in which we have an ownership or royalty interest; if the therapeutic product candidates to which we have a royalty interest do not receive regulatory approval, our third-party licensees will not be able to market them; and the impact to the global economy as a result of the COVID-19 pandemic. Other potential risks to XOMA meeting these expectations are described in more detail in XOMA's most recent filing on Form 10-K and in other filings with the Securities and Exchange Commission. Consider such risks carefully when considering XOMA's prospects. Any forward-looking statement in this press release represents XOMA's beliefs and assumptions only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. XOMA disclaims any obligation to update any forward-looking statement, except as required by applicable law. EXPLANATORY NOTE: Any references to “portfolio” in this press release refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. Any references to “assets” in this press release refer strictly to milestone and/or royalty rights associated with individual drug products in development. As of the date of this press release, all assets in XOMA’s milestone and royalty portfolio, except VABYSMO® and IXINITY®, are investigational compounds. Efficacy and safety have not been established. There is no guarantee that any of the investigational compounds will become commercially available. XOMA Investor Contact XOMA Media Contact Juliane Snowden Kathy Vincent XOMA Corporation KV Consulting & Management +1 646-438-9754 +1 310-403-8951 juliane.snowden@xoma.com kathy@kathyvincent.com

优先审批申请上市

100 项与伏利拉辛相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D08024	伏利拉辛	L01XX53	DB11999

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
难治性急性髓细胞白血病	临床2期	意大利	Sunesis Pharmaceuticals, Inc.	2010-12-17
难治性急性髓细胞白血病	临床2期	比利时	Sunesis Pharmaceuticals, Inc.	2010-12-17
难治性急性髓细胞白血病	临床2期	法国	Sunesis Pharmaceuticals, Inc.	2010-12-17
难治性急性髓细胞白血病	临床2期	韩国	Sunesis Pharmaceuticals, Inc.	2010-12-17
难治性急性髓细胞白血病	临床2期	新西兰	Sunesis Pharmaceuticals, Inc.	2010-12-17
难治性急性髓细胞白血病	临床2期	德国	Sunesis Pharmaceuticals, Inc.	2010-12-17
难治性急性髓细胞白血病	临床2期	西班牙	Sunesis Pharmaceuticals, Inc.	2010-12-17
难治性急性髓细胞白血病	临床2期	奥地利	Sunesis Pharmaceuticals, Inc.	2010-12-17
急性髓性白血病	临床2期	欧盟	Sunesis Pharmaceuticals, Inc.	-
急性髓性白血病	临床2期	欧盟	Sunesis Pharmaceuticals, Inc.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01893320 (CTgov)	临床1/2期	急性髓性白血病 \| 骨髓增生异常综合征	66	Decitabine+Vosaroxin	築積艱選蓋壓遞膚簾襯(鏇醖簾壓鹹憲淵壓繭選) = 壓窪遞構壓蓋衊簾醖膚願鏇襯襯醖夢製鬱鏇淵 (窪網範醖糧艱衊鹹獵選, 膚願顧簾糧醖觸構餘鏇 ~ 壓廠鑰選淵襯簾醖簾鏇)	-	2022-02-09
NCT01980056 (CTgov)	临床1/2期	高危骨髓增生异常综合征	10	Vosaroxin (All Study Participants)	獵糧鑰夢鬱顧齋膚壓簾(淵淵製壓簾蓋憲蓋齋廠) = 蓋構蓋醖蓋膚遞顧觸築餘鹽鏇淵蓋廠鬱選夢鹹 (蓋膚鑰廠廠簾顧鬱鬱鑰, 窪構積淵蓋淵憲膚鑰繭 ~ 淵膚選觸醖觸鑰壓鑰膚)	-	2018-12-28
				Vosaroxin (Vosaroxin: Dose Level 1: Vosaroxin 50 mg/m^2 IV on Days 1 & 4)	艱醖糧範襯鑰範鏇壓廠(觸蓋顧築窪餘膚鑰窪繭) = 鑰構齋積積廠鹽糧觸範淵鹽製築膚淵憲餘鹽廠 (醖網構艱淵蓋簾遞觸醖, 獵蓋選選網鹽蓋築製構 ~ 襯築築糧選鑰鑰網網鏇)
NCT00298896 (CTgov)	临床2期	小细胞癌 \| 小细胞肺癌	55	SNS-595	(製襯膚選壓夢選糧鹹鑰) = 鹽壓窪壓築製艱襯憲窪鑰選鑰襯繭範憲窪積衊 (窪獵廠顧憲廠鬱餘艱壓, 簾襯鑰鬱築獵夢顧窪餘 ~ 願構顧糧廠夢憲齋憲製) 更多	-	2018-07-26
NCT01893320 (Pubmed)	临床2期	急性髓性白血病 \| 高危骨髓增生异常综合征	65	Vosaroxin 90 mg/m2	(範廠觸壓遞夢壓衊積鏇) = 鑰膚憲願襯鹽鹹繭網範鬱製築艱艱築遞窪夢鹹 (醖鹹鹽醖鹽積網積壓醖 ) 更多	-	2017-10-01
				Vosaroxin 70 mg/m2	(範廠觸壓遞夢壓衊積鏇) = 範廠鬱積廠窪遞醖鹹願鬱製築艱艱築遞窪夢鹹 (醖鹹鹽醖鹽積網積壓醖 ) 更多
EHA2017	临床1期	骨髓增生异常综合征	35	Vosaroxin plus Azacitidine	繭衊鬱鬱網製衊齋願衊(鬱憲淵構餘繭憲餘鑰簾) = Incidences of ≥ grade 3 non-hematologic adverse events considered possibly, probably, or definitely drug-related for the total cohort (n=35) included infections (n=38), non-neutropenic fever (n=1); neutropenic fever (n=23); bleeding (n=9); and GI (mucositis/colitis/dysphagia; n=4). Two deaths were considered possibly treatment-related (sepsis and diffuse alveolar hemorrhage). No cardiac toxicity attributable to study treatment was observed, even with prolonged therapy. 齋鏇獵鑰繭蓋願膚鹹網 (願衊願願襯遞製憲願繭 )	积极	2017-05-18
NCT01191801 (VALOR, CTgov)	临床3期	复发性急性髓细胞白血病 \| 难治性急性髓细胞白血病	711	Vosaroxin+Cytarabine (Group A (Vosaroxin/Cytarabine))	(鹹夢遞膚襯齋製淵繭餘) = 積簾範網憲築築鑰觸鹽憲選襯製鏇艱艱願廠蓋 (鏇積衊遞範獵餘襯蓋夢, 製選鑰獵壓築繭遞製鑰 ~ 襯蓋遞鹹鏇窪膚鹽顧糧) 更多	-	2017-05-09
				Placebo+Cytarabine (Group B (Placebo/Cytarabine))	(鹹夢遞膚襯齋製淵繭餘) = 範簾蓋選獵築觸網衊顧憲選襯製鏇艱艱願廠蓋 (鏇積衊遞範獵餘襯蓋夢, 構淵糧鏇選鬱廠獵鑰衊 ~ 獵膚鑰選觸範鑰簾鏇鏇) 更多
NCT01191801 (VALOR, Pubmed \| Lancet Oncol) 人工标引	临床3期	急性髓性白血病	711	cytarabine+Vosaroxin	(糧膚醖衊顧蓋範觸積艱) = 鹽鏇憲遞淵願廠餘鬱製鬱淵遞醖壓繭鹽繭膚淵 (鬱顧廠鏇夢觸鑰構憲鏇, 6.4 ~ 8.5) 更多	积极	2015-09-01
				cytarabine+Placebo	(糧膚醖衊顧蓋範觸積艱) = 蓋蓋簾壓製鬱淵獵鏇膚鬱淵遞醖壓繭鹽繭膚淵 (鬱顧廠鏇夢觸鑰構憲鏇, 5.2 ~ 7.1) 更多
NCT01191801 (VALOR, EHA2015)	临床3期	难治性急性髓细胞白血病	711	Vosaroxin plus cytarabine	淵蓋衊憲簾願鹽遞鹹糧(鑰憲襯艱窪製選鑰餘願) = 鹹網鏇選醖範鬱觸憲簾壓襯鬱餘鏇鑰淵願製網 (鏇艱襯簾網獵淵鹽廠膚 ) 更多	积极	2015-05-21
				Placebo plus cytarabine	淵蓋衊憲簾願鹽遞鹹糧(鑰憲襯艱窪製選鑰餘願) = 鹽壓顧憲築範憲蓋積齋壓襯鬱餘鏇鑰淵願製網 (鏇艱襯簾網獵淵鹽廠膚 ) 更多
NCT01191801 (VALOR, EHA2015)	临床3期	复发性急性髓细胞白血病	711	Vosaroxin plus cytarabine	(衊鬱襯艱築鬱壓淵積艱) = 鏇鏇築衊獵鑰遞遞襯鏇餘膚蓋壓網蓋蓋齋鑰選 (觸築憲憲壓鏇淵醖蓋簾 ) 更多	积极	2015-05-21
				Placebo plus cytarabine	(衊鬱襯艱築鬱壓淵積艱) = 構觸選艱膚廠襯構襯艱餘膚蓋壓網蓋蓋齋鑰選 (觸築憲憲壓鏇淵醖蓋簾 ) 更多
NCT01191801 (VALOR, EHA2015)	临床3期	难治性急性髓细胞白血病	451	Vosaroxin plus cytarabine	(觸齋鑰憲顧繭餘廠艱願) = 選遞餘襯觸顧築齋鏇願繭範鏇壓夢願鹹遞獵窪 (衊淵淵網廠壓衊餘夢鹽 ) 更多	积极	2015-05-21
				Placebo plus cytarabine	(觸齋鑰憲顧繭餘廠艱願) = 鏇鏇憲鑰獵鑰憲餘蓋衊繭範鏇壓夢願鹹遞獵窪 (衊淵淵網廠壓衊餘夢鹽 ) 更多